The Necessary of Antibody Pharmaceutical Property Development
Antibodies shed light on the treatment of cancers and numerous other complicated diseases. However, their poor pharmaceutical properties such as poor thermostability and chemical stability are not conducive to the retention of their biological activity, which leads to antibodies being prone to aggregation and thus producing strong immunogenicity. A larger concentration is required to provide the intended therapeutic effect. Therefore, it is highly important to increase the pharmacological characteristics of antibodies.
Fig. 1 Promising design of heterodimeric bispecific antibodies.1,2
Antibody Pharmaceutical Property Development Service at Creative Biolabs
With our expertise in antibody engineering, Creative Biolabs is proud to offer an antibody pharmaceutical property development service to assist clients in applying their antibody research into clinical settings. We utilize cutting-edge computer-aided structure design technologies to optimize antibody sequences and structures, ensuring precise antibody distribution within the body. Our team also employs various assays, both model-dependent and independent, helping to pick the most suitable therapeutic delivery methods and evaluate the pharmacokinetics of improved antibodies. Our goal at Creative Biolabs is to provide clients with high-quality antibodies quickly and efficiently, meeting your diverse needs and driving advancements in healthcare and therapeutics.
Fig. 2 Antibody pharmaceutical property development service.
Development Strategies Available at Creative Biolabs
Antibody Thermostability Improvement
Inadequate thermostability of antibodies leads to aggregation and lower expression levels. Research indicates that modifying the hydrophobic core and charge cluster residues is essential for enhancing the thermostability of antibodies. Based on this, we provide several optimizing strategies for superior antibody thermostability:
-
Modification of amino acids in the VH/VL interface.
-
Removal of hydrophobic residues from the antibody surface.
-
Optimizing conserved amino acid residues.
Antibody Solubility Improvement
An essential aspect of the successful administration of therapeutic antibodies in patients is ensuring a high concentration of the formulation. This is especially important for addressing chronic diseases. To meet this requirement, clinical candidate antibodies need to possess excellent solubility and minimal viscosity. Our service has the potential to act as an effective tool to improve antibodies' solubility by drawing on the following:
-
Decrease of the antibody's surface hydrophobicity.
-
Introducing N-linked glycosylation into a CDR region to engineer the antibody.
-
Altering the antibody's isoelectric point.
Antibody Chemical Stability Improvement
Numerous chemical degradation processes can impact the stability of antibodies, potentially diminishing their therapeutic potency. We present various strategies aimed at eliminating degradation sites from the surface structure of antibodies to enhance their chemical stability.
-
Prevention of antibody deamidation.
-
Avoiding antibody isomerization.
-
Prevention of succinimide formation.
-
Prevention of methionine and tryptophan oxidation.
-
Avoiding cysteinylation of unpaired cysteines in the CDR region.
Antibody Heterogeneity Reduction
Variations in posttranslational modifications, like glycosylation and N-pyroglutamine cyclization, can result in antibody heterogeneity and inconsistencies in antibody quality across different batches, leading to increased production costs for antibody applications. Therefore, our service provides pathways to suppress these processes that improve the homogeneity of antibodies.
-
Prevention of antibody glycosylation and N-pyroglutamine cyclization
Advantages of Our Antibody Pharmaceutical Property Development Service
-
Computer-aided methods provide precision and efficacy.
-
Rapid timelines drive antibodies to market.
-
Comprehensive analysis for improved antibodies.
-
Project node communication minimizes the probability of failure.
Are you currently facing challenges with the production of a therapeutic antibody, such as low yield, high levels of aggregation, or difficulties in purification? Please don't hesitate to reach out to us for more details. Our specialized team will help in optimizing your antibody into a successful therapeutic product.
References
-
Abdeldaim, Dalia T., and Katharina Schindowski. "Fc-engineered therapeutic antibodies: recent advances and future directions." Pharmaceutics 15.10 (2023): 2402.
-
Distributed under Open Access license CC BY 4.0, without modification.
All products and services are for Research Use Only. Do Not use in humans.
